Yasmin - A new oral contraceptive, a new progestogen: The reasons why

European Journal of Contraception and Reproductive Health Care

Volumn 5, Issue SUPPL. 3, 2000, Pages 9-16

  Mansour, D ^a  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

Acceptability; Antimineralocorticoid properties; Discontinuation; Drospirenone; Non contraceptive health benefits; Oral contraceptive; Teenage pregnancy

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; GESTAGEN; MINERALOCORTICOID ANTAGONIST; ORAL CONTRACEPTIVE AGENT;

ACNE; ADOLESCENT PREGNANCY; BODY WEIGHT DISORDER; CONFERENCE PAPER; DEMOGRAPHY; FEMALE; FEMALE STERILIZATION; HUMAN; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEBORRHEA; WATER RETENTION;

ANDROSTENES; CONTRACEPTIVES, ORAL, SYNTHETIC; FEMALE; HUMANS; PATIENT COMPLIANCE; PROGESTERONE CONGENERS;

EID: 0034471449     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Attitudes to current oral contraceptive use and future developments: The women's perspective
2. The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential
3. The public health implications of the 1995 'pill scare'
4. Teenage Pregnancy
5. Contraceptive failure rates based on the 1988 NSFG
6. What do women use when they stop using the pill
7. Use and misuse of oral contraceptives by adolescents attending a free-standing clinic
8. Contraceptive failure in the United States: An update
9. Trends in contraceptive use in the United States: 1982-1995
10. A longitudinal study of birth control and pregnancy outcome in a Swedish population
11. Comparison of continuation rates for hormonal contraception among adolescents
12. Women's efforts to prevent pregnancy: Consistency of oral contraceptive use
13. Determinants of contraceptive use among women of reproductive age in Great Britain and Germany. I. Demographic factors
14. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris
15. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms